 Connection
Andrew Bradford to E2F Transcription Factors
This is a "connection" page, showing publications Andrew Bradford has written about E2F Transcription Factors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.396 |
|
|
|
-
Kurayoshi K, Shiromoto A, Ozono E, Iwanaga R, Bradford AP, Araki K, Ohtani K. Ectopic expression of the CDK inhibitor p21Cip1 enhances deregulated E2F activity and increases cancer cell-specific cytotoxic gene expression mediated by the ARF tumor suppressor promoter. Biochem Biophys Res Commun. 2017 01 29; 483(1):107-114.
Score: 0.148
-
Kitamura H, Ozono E, Iwanaga R, Bradford AP, Okuno J, Shimizu E, Kurayoshi K, Kugawa K, Toh H, Ohtani K. Identification of novel target genes specifically activated by deregulated E2F in human normal fibroblasts. Genes Cells. 2015 Sep; 20(9):739-57.
Score: 0.134
-
Nakajima R, Deguchi R, Komori H, Zhao L, Zhou Y, Shirasawa M, Angelina A, Goto Y, Tohjo F, Nakahashi K, Nakata K, Iwanaga R, Bradford AP, Araki K, Warita T, Ohtani K. The TFDP1 gene coding for DP1, the heterodimeric partner of the transcription factor E2F, is a target of deregulated E2F. Biochem Biophys Res Commun. 2023 06 30; 663:154-162.
Score: 0.057
-
Nakajima R, Zhao L, Zhou Y, Shirasawa M, Uchida A, Murakawa H, Fikriyanti M, Iwanaga R, Bradford AP, Araki K, Warita T, Ohtani K. Deregulated E2F Activity as a Cancer-Cell Specific Therapeutic Tool. Genes (Basel). 2023 02 02; 14(2).
Score: 0.056
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|